New bone drug LYN101 enters first human tests
NCT ID NCT07178327
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 33 times
Summary
This early-stage study tests a new drug called LYN101 in healthy volunteers and postmenopausal women with low bone mass, who are at risk for fractures. The goal is to check the drug's safety and how the body processes it. About 44 participants will receive either the drug or a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROTIC FRACTURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Sixth People's Hospital
Shanghai, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233060, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.